Patent
Anti-angiogenic compositions and methods of use
William L. Hunter,Lindsay S. Machan,A. Larry Arsenault +2 more
- 19 Jul 1994
1.2K
TL;DR: In this article, an anti-angiogenic factor and a polymeric carrier were used for embolization of blood vessels and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.
read more
Abstract: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Patent
Coated implantable medical device
Brian L. Bates,Anthony O. Ragheb,Neal E. Fearnot,Thomas G. Kozma,William D. Voorhees +4 more
- 31 Oct 2007
TL;DR: A coated implantable medical device as discussed by the authors includes a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract.
1.8K
Patent
Therapeutic inhibitor of vascular smooth muscle cells
Lawrence L. Kunz,Peter G. Anderson +1 more
- 15 Feb 1996
TL;DR: In this paper, the authors present methods for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.
1K
Patent
Medical devices and applications of polyhydroxyalkanoate polymers
Simon F. Williams,David P. Martin,Frank A. Skraly +2 more
- 24 Mar 2000
TL;DR: In this paper, the degradation times of polyhydroxyalkanoates are controlled under physiological conditions, and the degradation rates are controlled with less than one year under certain physiological conditions.
1K
Patent
Silver implantable medical device
Anthony O. Ragheb,Brian L. Bates,Neal E. Fearnot,Thomas A. Osborne,Thomas G. Kozma,Joseph W. Roberts,William D. Voorhees +6 more
- 23 Oct 1997
TL;DR: In this paper, a coronary stent implantable medical device is defined as a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract.
900
Patent
Drug coating with topcoat
Ni Ding,Michael N. Helmus +1 more
- 19 Jun 1998
TL;DR: In this paper, a method for a coating an implantable device or prosthesis is described, which includes an undercoat of polymeric material containing an amount of biologically active material, particularly heparin, dispersed therein.
850
References
Patent
Selective alteration of antibody immunogenicity
Thomas R. Sykes,Reddish Mark,Richard P. Baum,Antoine A. Noujaim +3 more
- 18 Mar 1993
TL;DR: In this paper, a simple process for modification of anti-TAA antibodies, which alters their immunogenicity so that their ability to induce an anti-isotypic response is selectively diminished, while they remain able to elecit an antiidiotypic response, is described.
4
•Journal Article
Classifying cytostatics on the basis of their angiocidal and angiostatic effects.
Pasi A,Qu B,Messiha Fs +2 more
TL;DR: A significant reduction of vessel counts (VC) due both to angiocidal and an angiostatic action, was induced by DOX, MXN, VP-16, VCR, and VLB, which might have implications for their use in the clinical treatment of malignant tumors.
4
A PROBE OF THE HUMAN PLASMIN‐α2‐MACROGLOBULIN INTERACTION UTILIZING MONOCLONAL ANTIBODIES TO HUMAN PLASMINa
TL;DR: These experiments have shown that alpha 2M may have a bait region capable of accommodating proteases of a far greater molecular weight than previously recognized, since antibody-plasmin complexes apparently become entrapped.
3
•Journal Article
Lobenzarit disodium (CCA) inhibits the proliferation of human endothelial cells and the activity of DNA polymerase alpha.
TL;DR: CCA is a potent inhibitor of DNA polymerase alpha and this inhibitory effect could cause the inhibition of endothelial cell proliferation, which may be related to the therapeutic and pharmacological mechanisms of CCA.
3
Related Papers (5)
Ni Ding,Michael N. Helmus +1 more
- 19 Jun 1998
Eric P. Berg,Ronald J. Tuch,Michael Dror,Rodney G. Wolff +3 more
- 07 Jun 1995